drugset / Trial / NCT01162915

Transfer of Bone Marrow Derived Stem Cells for the Treatment of Spinal Cord Injury

NCT01162915

Phase 1 Suspended 10 enrolled TCA Cellular Therapy
NaSingle-groupOpen-labelTreatment

Summary

This study is based on preclinical (animal) studies showing that infusing bone marrow-derived mesenchymal stem cells into the spinal fluid may contribute to improving neurologic function in animal models with spinal cord injuries. Bone marrow (BM) contains several types of stem cells that can produce functional cells. This includes cells that could help the healing process of damaged neurologic tissue. The primary objective of this study is to see if the injection of these cells, obtained from your own bone marrow, is safe. A secondary objective is to evaluate if the treatment can provide functional improvements (neuromuscular control and sensation) in the affected areas.

Timeline

Start
2010-07
Primary completion
2014-05
Completion
2014-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Autologous bone marrow-derived mesenchymal stem cells Cell therapy Intrathecal

Indications